eFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) — eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that Steve Worland, Ph.D., president, and chief executive officer of eFFECTOR, will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Wednesday, February 14th at 10:40 am ET.

A live webcast of the virtual presentations will be available on the “Events and Presentations” page of the Investors section of the Company’s website with a replay available for 90 days following the event. For more information, please visit investors.effector.com.

About eFFECTOR Therapeutics

eFFECTOR is a clinical-stage biopharmaceutical company pioneering the development of a new class of oncology drugs referred to as STRIs. eFFECTOR’s STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase interacting kinase (MNK). The eIF4F complex is a central node where two of the most frequently mutated signaling pathways in cancer, the PI3K-AKT-mTOR and RAS-MEK-ERK pathways, converge to activate the translation of select mRNA into proteins that are frequent culprits in key disease-driving processes. Each of eFFECTOR’s product candidates is designed to act on a single protein that drives the expression of a network of functionally related proteins, including oncoproteins and immunosuppressive proteins in T cells, that together control tumor growth, survival and immune evasion. eFFECTOR’s lead product candidate, tomivosertib, is a MNK inhibitor currently being evaluated in KICKSTART, a randomized, double-blind, placebo-controlled Phase 2b trial of tomivosertib in combination with pembrolizumab in patients with metastatic non-small cell lung cancer (NSCLC). Zotatifin, eFFECTOR’s inhibitor of eIF4A, is currently being evaluated in Phase 2a expansion cohorts in certain biomarker-positive solid tumors, including ER+ breast cancer and KRAS-mutant NSCLC. eFFECTOR has a global collaboration with Pfizer to develop inhibitors of a third target, eIF4E.

         
Investors:         Media:
Christopher M. Calabrese
Managing Director
LifeSci Advisors
917-680-5608
ccalabrese@lifesciadvisors.com
   Kevin Gardner
Managing Director
LifeSci Advisors
617-283-2856
kgardner@lifesciadvisors.com
   Mike Tattory
Account Supervisor
LifeSci Communications
609-802-6265
mtattory@lifescicomms.com

Staff

Recent Posts

Hazelden Betty Ford Foundation Announces Lineup for 75th Anniversary Gala

Rob Lowe to EmceeCenter City, Minnesota--(Newsfile Corp. - July 1, 2024) - On Friday, September…

3 hours ago

Highline Warren hiring at new Vacaville distribution center in California

Company offers competitive benefits and safety-focused cultureVACAVILLE, Calif., July 1, 2024 /PRNewswire/ -- Highline Warren…

3 hours ago

Putting Healthcare Quality on the Map (and in the Boardroom and the Budget)

New Campaign from The National Association for Healthcare Quality Raises Awareness of the Power of…

3 hours ago

DonorConnect, InVita Healthcare Technologies, and Specialist Direct Partner to Automate Diagnostic Test Reporting for Organ Donation

New telepathology interface will save critical hours and bolster patient safety by replacing current time-consuming…

3 hours ago

Voiceitt validates next-generation Voice AI in an innovative pilot for Deaf Individuals

In a program facilitated by Newlab, Voiceitt demonstrates the flexibility and inclusivity of its next-generation…

3 hours ago

Partillion Bioscience’s Nanovial Products Available in Japan Through Distribution by Sony

One-line Summary: Distribution by Sony in Japan Leverages Compatibility of Nanovial Technology with Sony's Flow…

3 hours ago